REGN vs STRD · P/E 14, rev $14.34B vs rev $463.5M
Regeneron Pharmaceuticals Inc (REGN) versus MicroStrategy Incorporated 10.00% Series A Perpetual Stride Preferred Stock (STRD) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
MicroStrategy Incorporated 10.00% Series A Perpetual Stride Preferred Stock (STRD) is a software - application company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported STRD revenue for 2024-12-31 was $463.5M. Net income was -$1.17B. Revenue was down 6.6% from 2023-12-31 to 2024-12-31. STRD currently screens at market cap $901.8M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. STRD currently screens at market cap $901.8M.
Not investment advice. Open the REGN and STRD stock pages for the full models.
Not investment advice.